No, Puma Biotechnology does not pay dividends. As a clinical-stage and commercial-stage biopharmaceutical enterprise, the company reinvests its incoming revenues from its cancer therapies directly back into research, development, clinical trial pipelines, and corporate debt management rather than distributing cash dividends to shareholders.